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Abstract In February 2014, a group of scientists convened as part of the University of California
Davis Cardiovascular Symposium to bring together experimental and mathematical modelling
perspectives and discuss points of consensus and controversy on the topic of sodium in the heart.
Thispaper summarizes the topicsofpresentationanddiscussion fromthe symposium,witha focus
on the role of aberrant sodiumchannels andabnormal sodiumhomeostasis in cardiac arrhythmias
and pharmacotherapy from the subcellular scale to the whole heart. Two following papers focus
onNa+ channel structure, function and regulation, andNa+/Ca2+ exchange andNa+/K+ ATPase.
The UC Davis Cardiovascular Symposium is a biannual event that aims to bring together leading
experts in subfields of cardiovascular biomedicine to focus on topics of importance to the field.
The focus onNa+ in the 2014 symposium stemmed from themultitude of recent studies that point
to the importance of maintaining Na+ homeostasis in the heart, as disruption of homeostatic
processes are increasingly identified in cardiac disease states. Understanding how disruption
in cardiac Na+-based processes leads to derangement in multiple cardiac components at the
level of the cell and to then connect these perturbations to emergent behaviour in the heart to
cause disease is a critical area of research. The ubiquity of disruption of Na+ channels and Na+
homeostasis in cardiac disorders of excitability and mechanics emphasizes the importance of a
fundamental understanding of the associated mechanisms and disease processes to ultimately
reveal new targets for human therapy.
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Disruption of sodium homeostasis in cardiac disease
In the session on ‘Disruption of Na+ homeostasis, Sanda
Despa, Brian O’Rourke, Donald Bers, Alicia Mattaizzi,
William Louch, Christoph Maack and Sridharan Rajamani
were presenters, discussion leaders and panelists. Below is a
summary of the sessions and discussion.
Although it is well known that the normal cycling
of intracellular Ca2+ in cardiac myocytes is critical for
the normal electrical and mechanical functioning of the
heart, the intracellular Na+ concentration ([Na+]i) is
tightly coupled to Ca2+ homeostasis and is increasingly
recognized as a modulating force of cellular excitability,
frequency adaptation and cardiac contractility (Faber &
Rudy, 2000; Grandi et al. 2010; Despa & Bers, 2013;
Fig. 1). The direct coupling between intracellular Na+ and
Ca2+ concentrations is mediated via the sodium–calcium
exchanger (NCX), which exchanges 3 Na+ for each Ca2+,
and comprises the primary cellular extrusion mechanism
for Ca2+ (Blaustein & Lederer, 1999). The NCX can
operate in both forward mode, during which it extrudes
Ca2+, or can mediate Ca2+ influx when it operates in the
‘reverse mode’. The activity of NCX is sensitively tuned to
changes in [Na+]i so that a millimolar increase in [Na+]i
resulting fromchanges in the ion influx/efflux balance, can
result in changes to NCX activity that alter Ca2+ homeo-
stasis leading to intracellular Ca2+ loading in both cellular
and sarcoplasmic reticulum (SR) compartments (Maack
et al.2006).Aconsequenceof intracellular cardiacmyocyte
Ca2+ loading is stronger contraction (Pieske et al. 2002),
but NCX-dependent Ca2+ loading may compromise the
stability of the SR store, thus facilitating larger Ca2+ trans-
ients and/or spontaneousCa2+waves as indigitalis toxicity
(Despa & Bers, 2013). If Ca2+ waves or transients are
sufficiently large, the excess intracellular Ca2+ will be
extruded via the NCX resulting in depolarizing current
that may bring the membrane potential of the cell to
the voltage threshold required for activation of the Na+
channel, causing delayed after-depolarizations (DADs)
and arrhythmogenically triggered action potentials
(Despa & Bers, 2013). For a more detailed description
of structural and functional determinants of NCX,
please refer to the white paper no. 3 (Shattock et al.
2015).
An additional important cellular mechanism for
the maintenance of [Na+]i homeostasis is the
sodium–potassium ATPase (NKA), which uses energy
derived from hydrolysis of an ATP molecule, allowing
extrusion of three Na+ ions in exchange for two K+
ions. The NKA is half-maximally activated between 10
and 22 mM [Na+]i and between 1 and 2 mM external
K+ (Glitsch, 2001). Thus, at 4 mM normal extracellular
K+, NKA is70% saturated, with plenty of available ATP
(5–10 mM) (half-maximal NKA activation is 80–150 μM)
(Hilgemann et al. 1991). The regulation and function of
NKA is covered in detail in white paper no. 3 (Shattock
et al. 2015).
Cardiac myocytes also contain Na+ transport
mechanisms that promote simultaneous maintenance
of [Na+]i homeostasis and physiological pH including
the sodium–hydrogen exchanger (NHE), which moves
sodium into the cell in exchange for proton export (Leem
et al. 1999). The sodium–bicarbonate symporter (NBC)
is also present in myocytes and acts as an additional
mechanism to couple [Na+]i homeostasis and pH (Leem
et al. 1999).
In disease states, the importance of the proper
coupling between multiple Na+ homeostatic mechanisms
is evident. In ischaemia, failure of ion homeostasis starts
with an influx of Na+ through the NHE (Eigel & Hadley,
1999) in an attempt to raise the acidified pH (through
the extrusion of H+). In ischaemia/reperfusion injury,
activation of the NHE and NBC, a pathological increase
in the persistent/late Na+ current (INaL), Na+ entry
through connexin hemichannels (at least in isolated myo-
cytes) (Kondo et al. 2000), and NKA inhibition result in
reverse mode NCX activity that leads to Ca2+ overload
(Despa & Bers, 2013). During hypoxia, NHE in rabbit
ventricular myocytes has been shown to dominate total
Na+ influx (Bers et al. 2003). Inhibition of the NHE
during ischaemic episodes attenuates the rise in intra-
cellular [Na+]i (Avkiran, 2003; Baetz et al. 2003). Along
with Na+ influx via the NHE, a parallel decrease in energy
production due to mitochondrial dysfunction and loss
of ATP results in reduced Na+ elimination through the
Na+/K+ATPase (Hale et al.2008),which further augments
[Na+]i. The above examples show how disruptions to
[Na+]i homeostasis are evident in multiple disease states
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and occur via distinct mechanisms that can lead to a
pathological cascade through coupled Na+ regulatory
mechanisms that ultimately leads to disruptions in Ca2+
homeostasis.
Another key disease state marked by intracellular
sodium dysregulation is heart failure (HF), where it
has been shown that [Na+]i is elevated in humans and
numerous animal models (Despa et al. 2002; Pieske et al.
2002; Baartscheer et al. 2003; Schillinger et al. 2006; Louch
et al. 2010). Elevation of [Na+]i in HF may represent a
compensatory adaptation that allows for an increase in
Ca2+ influx viaNCX, leading to improved contraction, as a
type of physiological ‘digitalis’. However, increased [Na+]i
has also been associated with diastolic dysfunction, as it
impairs Ca2+ removal by NCX (Louch et al. 2010, 2012)
and with energetic defects and oxidative stress (Kohlhaas
et al. 2010; Bay et al. 2013; Nickel et al. 2014), of which
the latter may contribute to the progression of the disease
through inducing cell death and maladaptive remodelling
(Nickel et al. 2014).
Question or controversy: sodium dysregulation
While there is little doubt that the sodiumdysregulation
is important in numerous cardiac pathologies, a
detailed understanding of the precise mechanisms is
missing.
Which are the critical pathways toNa+ overload in each
disease?
How does disease-linked remodelling alter ion homeo-
static mechanisms?
Which disease-linked changes in Na+ processes are
compensatory?
While it is generally agreedupon that [Na+]i is increased
in many forms of heart disease, the specific pathways
responsible for the increase in intracellular Na+ in some
diseases are still a matter of controversy. Increased Na+
entry through Na+ channels and NHE and decreased Na+
extrusion by reduced NKA activity have been reported
for various animal models of disease. It could well be
that the specific pathway is both species and model
dependent. For example, NKA expression is reduced
in failing human myocardium (Schwinger et al. 1999),
although mRNA levels are unchanged (Allen et al. 1992).
In the rat, mRNA and protein levels of the primary
NKA α1 isoform are preserved in most HF models,
whereas the protein levels of NKA α2 are apparently
reduced, while NKA α3 is increased (Verdonck et al.
2003). In rabbit HF models all NKA isoforms have been
shown to exhibit reduced protein expression in myo-
cytes (Bossuyt et al. 2005). Clearly, a direct causative
link between biochemical changes and function cannot
be made because of potential confounding factors such as
altered protein regulation, function or activity that are not
measured with biochemical assays. An example here is the
differential regulation of NKA by phospholemman (PLM)
in HF, described in detail in white paper no. 3 (Shattock
et al. 2015). Moreover, there are important changes in
localization of NKA isoforms during heart failure. Swift
et al. showed altered expression patterns of NKA α1 and
NKA α2 isoforms, which were linked to altered Ca2+
extrusion from cardiomyocytes and consequent changes
in contractile parameters (Swift et al. 2008).
A large Na+ influx via other mechanisms has
also been proposed to increase [Na+]i in HF.
For example, a TTX-sensitive diastolic Na+ influx
(implicating involvement of the voltage-gated Na+
channel, although the specific isoform is unclear) was
observed to be upregulated in rabbits with pressure
and volume overload-induced HF (Despa et al. 2002).
NHE upregulation has also been documented in HF
(Baartscheer et al. 2003). Acidosis was also shown to
promote Na+ loading in the sarco/endoplasmic reticulum
Ca2+-ATPase (SERCA) knockout mouse (Li et al. 2012).
Na+ influx also occurs as a result of a gain of function
of the Na+ channel in the form of the non-inactivating
component INaL that will be detailed in the following
sections.
Question or controversy: Na+ handling in disease
How do various isoforms of Na+ transport processes
contribute to function or disease?
How does modification to individual Na+ transport
isoforms alter function?
Do changes measured in animal models reflect human
adaptive processes?
In summary, while dynamic beat-to-beat changes in
[Na+]i allow physiological adaptation in non-diseased
cardiacmyocytes, perturbations toNa+ homeostasis occur
through a variety of mechanisms in cardiac disease states.
Disease-induced disruption to [Na+]i maintenance occurs
because the pumps and exchangers described above are
unable to adequately compensate for pathological Na+
loading without a consequent disruption in Ca2+ homeo-
stasis. Not only does Ca2+ overload have the potential
to disrupt electrical activity in the heart, it also has
detrimental effects on cardiac energetics and metabolism.
Elevated [Na+]i is linked to disruptions in cardiac
energetics and metabolism
Although increased [Na+]i may improve the contractile
function of the diseased heart, elevated [Na+]i may have a
pathological impact on cardiac metabolism and oxidative
state. For example, the increase in [Na+]i and reversemode
NCX-mediated Ca2+ influx during the cardiac action
potential is energetically less efficient thannormal SRCa2+
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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release and may contribute to a mismatch between energy
supply and demand in the failing heart (Weisser-Thomas
et al. 2003). Furthermore, when intracellular Ca2+ trans-
ients were triggered by NCX-mediated Ca2+ entry, the
efficiency of mitochondrial Ca2+ uptake is substantially
reduced, suggesting reduced efficiency in the transport
mechanism necessary (of NCX vs. Ca2+ current and SR
Ca2+ release) to drive Ca2+-induced stimulation of Krebs
cycle processes (Kohlhaas & Maack, 2010). An interesting
point to consider and that needs further clarification is
what is the magnitude of mitochondrial Ca2+ uptake
occurringoneachheartbeat andhowdokinetics ofuptake,
release and buffering impact cytoplasmic systolic and
diastolic Ca2+ signals.
In failing cardiac myocytes, increased [Na+]i impairs
energy supply-and-demand matching by promoting
acceleration of mitochondrial Ca2+ efflux, via the
mitochondrial Na+/Ca2+ exchanger (mNCE, or NCLX),
which extrudes Ca2+ from the mitochondria in exchange
for Na+ (Liu & O’Rourke, 2008; Palty et al. 2010). This
effect, together with the decreased amplitude of cyto-
solic Ca2+ transients in HF, blunts mitochondrial Ca2+
signalling to the Krebs cycle during increased work,
resulting in oxidation of the pyridine nucleotide pool
(NAD(P)H), thus further compromising NADH supply
for oxidative phosphorylation (Liu & O’Rourke, 2008).
Additionally, sinceNADPH is required tomaintainmatrix
antioxidant pathway flux, its oxidation causes cellular
overload of reactive oxygen species (ROS) (Kohlhaas et al.
2010; Liu et al. 2010). ROS accumulation then contributes
to oxidative modification of Ca2+ handling and ion
channel targets to promote arrhythmias. This cascade of
failures, stemming from [Na+]i overload, is thus hypo-
thesized to provoke triggered arrhythmias (Liu et al. 2010),
which, in the context of the altered electrophysiological
substrate in HF, may induce sudden cardiac death (SCD).
Interestingly, chronic inhibition of the mNCE during the
induction ofHF prevents thesemitochondrial defects, and
abrogates cardiac decompensation and sudden death, in a
guinea pig model of HF/SCD (Liu et al. 2014).
Question or controversy: energetics andmetabolism
Howmuch mitochondrial Ca2+ uptake occurs on each
heartbeat?
How do the kinetics of uptake, release and buffering
influence cytoplasmic systolic and diastolic Ca2+
signals?
Abnormal sodium channel function in cardiac disease
In the session on ‘Na+-induced arrhythmias: from the
cellular level to the whole heart’, Penelope James Weiss,
Ole Sejersted, Jonathan Lederer, Zhilin Qu and Livia Hool
comprised the group of presenters, discussion leaders and
panelists. A summary of the session and discussion is below.
In addition to changes in [Na+]i homeostatic
mechanisms in the heart, changes to the distribution and
function of cardiac Na+ channels have been linked to
disease manifestation and progression of both inherited
and acquired cardiac arrhythmias. Either gain or loss
of Na+ channel function can result, depending on
the disease state, and both disruptions can lead to
proarrhythmic consequences arising from alterations in
cardiac conduction and repolarization.
Loss of Na+ channel function. In the case of loss of Na+
channel function, either as a result of disease-induced
remodelling or as a result of drug application, reducedNa+
current (INa) can cause insufficient cellular excitability
to allow propagation of electrical waves, leading to a
well-known requirement for some types of re-entrant
arrhythmias: conduction block.
One instance of remodelling of Na+ channels that
plays a role in conduction block and arrhythmogenesis
is in the infarct border zone where the electrical sub-
strate is extensively remodelled compared to normal
non-infarcted epicardium. The fact that progressive
electrical remodelling that occurs in chronic disease states
has been identified as a biomarker for sudden cardiac
death indicates the critical importance of revealing its
mechanisms (Gaudron et al. 2001; Goldberger et al.
2014). Na+ currents (as well as Ca2+ and K+ currents)
in cells isolated from the epicardial border zone (EBZ)
of 5-day- infarcted hearts have been shown to have both
altered current amplitudes and changes in kinetics (Lue &
Boyden, 1992; Aggarwal & Boyden, 1995; Pu & Boyden,
1997; Dun et al. 2004) consistent with reduced cellular
action potential (AP) amplitudes and upstroke velocity
and prolonged post-repolarization refractoriness. Within
the re-entrant circuit, two distinct cell regions have been
identified: cells from the central common pathway of the
circuit (IZc) and cells from the outer pathway on the other
side of the line of block (outer pathway, IZo; Baba et al.
2005). Cells from both of the infarct zone regions had
reduced Na+ current density, but the cells from the IZo
also exhibited slowerNa+ channel kinetics for time to peak
and current decay (Pu & Boyden, 1997). These changes in
Na+ channel function along with observed changes to
L-type Ca2+ currents give rise to electrical anisotropy that
promotes stable lines of block within the zone (Cabo &
Boyden, 2003). These stable lines of block then allow for
the development of sustained re-entrant excitation and
stable ventricular tachycardias in the EBZ (Janse & Wit,
1989).
If regional differences of ionic currents in cells of the
EBZ are the mechanisms underlying the lines of block
observed in the EBZ, then restoration of either the Na+
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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channel or the L-type Ca2+ channel availability, and
thereby normal function, should be antiarrhythmic by
disrupting the stability of the lines of block leading to
termination of re-entry. Indeed, recent studies (Coronel
et al. 2010) suggest that gene transfer-mediated over-
expression of the skeletal muscle sodium channel SkM1
resulted in improved Na+ channel availability in cells of
the EBZ because SkM1 channels have positively shifted
kinetics of inactivation rendering themavailable to open at
depolarized potentials at which cardiac Na+ channels are
not available. SkM1 overexpression improved conduction
and reduced the incidence of inducible ventricular tachy-
cardia/ventricular fibrillation (VT/VF) post-myocardial
infarction (Boink et al. 2012). Such approaches constitute
the potential for new development of strategic inter-
ventions to restore electrical disruptions in the heart
arising from electrically based remodelling.
Question or controversy: remodelling in the infarct
border zone
How can stability of functional lines of block be
disrupted to promote the termination of re-entry?
Gain of Na+ channel function. Recent work has focused
on gain-of-function of the Na+ current because a range
of cardiac diseases are marked by pathological increases
in the persistent late Na+ current component (late Na+
current, INaL) that follows the rapid transient activation of
INa. INaL is upregulated in many pathological conditions,
such as in the failing and/or ischaemic heart, in the heart
exposed to oxidative stress, and in hearts of patients with
congenital longQT3 syndromes (Bennett et al. 1995;Wang
et al. 1995; Maltsev et al. 1998a; Maltsev & Undrovinas,
2006; Song et al. 2006; Hund et al. 2008; Sossalla et al.
2010). Ca2+ dysregulation results in pathological effects
to promote INaL (Mori et al. 2000; Wingo et al. 2004)
via activation of Ca2+/calmodulin-dependent protein
kinase II (CaMKII) (Wagner et al. 2006), increased
mitochondrial oxidative phosphorylation (Belardinelli
et al. 2006) and consequent increased ROS (Kohlhaas
et al. 2010; Liu et al. 2010). Likewise increases in INaL,
which may lead to an increase in intracellular Ca2+ can
cause activation of CaMKII (Yao et al. 2011). Please
see Chen-Izu et al. (2015) for detailed descriptions of
Na+ channel regulation. Enhanced INaL leads to action
potential prolongation, disruption of normal cellular
repolarization, development of arrhythmia triggers, and
propensity to ventricular arrhythmia. In heart failure,
pharmacological targeting of INaL has been shown to
result in: (1) stabilization of repolarization; (2) decrease in
beat-to-beat action potential duration (APD) variability;
and (3) improvement in Ca2+ handling and contra-
ctility (Maltsev et al. 1998b; Undrovinas et al. 1999, 2006;
Undrovinas & Maltsev, 2008).
At least three distinct alterations in NaV1.5 (the
cardiac isoform of the voltage gated Na channel)
gating have been shown to increase INaL including the
Na+ window currents, differential gating modalities,
and non-equilibrium gating. These mechanisms were
initially revealed via detailed electrophysiological study
of mutations in SCN5A that resulted in long QT type
3 syndrome (LQT3) in patients. The window current
describes the INa that is measurable in the voltage range
where the steady-state inactivation curve and activation
curve overlap (January&Riddle, 1989; Zeng&Rudy, 1995;
Zaza et al. 2008). The current can be observed within
the ‘window’ of voltage during cardiac repolarization
or as a steady-state equilibrium current during voltage
clamp. The window can be affected by changes to the
activation and inactivation gating that result in widening
of the voltage range. In addition to mutations and poly-
morphisms, there have been a number of physiological
modulators identified including Ca2+, calmodulin and
phosphorylation (discussed in Chen-Izu et al. 2015) that
can increase the voltage range of the window (Zeng &
Rudy, 1995).
The bursting of Na+ channels is a well-described gating
mode where channels undergo a transient failure of
channel inactivation. Maltsev and Undrovinas recorded
INaL from heterologously expressed NaV1.5 in the absence
of other isoforms (Maltsev & Undrovinas, 2006), showing
that bursting channels were indeed of the same form
as those underlying the transient inward Na+ current.
Clancy et al. recorded and modelled the transitions from
normally inactivating Na+ channels to bursting channels
in heterologously expressed single NaV1.5 channels. A
computational model based on these rates was then used
to predict the magnitude and rate dependence of INaL
expected from ensemble currents (Clancy et al. 2002).
Non-equilibrium gating describes another form of
INaL that is not observed during typical voltage clamp
depolarization protocols (Clancy et al. 2003). However,
in response to a negative ramp current, a transient inward
Na+ current is observed. The amplitude of the current
is sensitively dependent on the rate of recovery from
inactivation, where faster recovery or a shift in the voltage
dependence of recovery from inactivation promotes the
current. Just as for the window current, non-equilibrium
INa is affected by a number of physiological modulators
including calmodulin and phosphorylation (Herren et al.
2013; Chen-Izu et al. 2015).
Gating abnormalities of the cardiac Na+ channel were
reported by Maltsev and Undrovinas in their description
of a novel, ultraslow inactivatingNa+ current, INaL, in both
normal and failing human hearts (Maltsev et al. 1998a).
The same group also showed an increased density and
slower inactivation kinetics of INaL (Maltsev et al. 2007)
in chronic heart failure as compared to normal hearts.
In single channels, two modes of gating underlying late
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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INa were observed: late scattered mode gating and burst
mode of gating that had slower kinetics in failing human
ventricular myocytes compared to non-failing ventricular
myocytes (Maltsev & Undrovinas, 2006). Importantly,
there were no differences in the unitary conductance of
INaL current between normal and failing human hearts,
suggesting a single population of channels in which this
gating phenotype is upregulated in HF (Undrovinas et al.
2002).
Question or controversy: Na+ channel defects
What are the disease-specific mechanisms leading to
pathological increases in INaL?
Are Na+ currents measured from human ‘non-failing’
myocytes the same as those from ‘normal’ myocytes?
Linking Na+ and Na+ channel abnormalities
to arrhythmias
Disruptions in Na+-based processes in the heart foster
arrhythmias by multiple mechanisms, depending on the
specific perturbation to the Na+-linked process. Of major
benefit to revealing and understanding themechanisms of
Na+-based arrhythmias is the development of numerous
new experimental techniques including examples such
as targeted subcellular imaging (Agarwal et al. 2011,
2014; Lederer et al. 2012; Despa et al. 2014), SR Ca2+
imaging (Wang et al. 2014), advances in electrophysiology
(Horvath et al. 2013), ‘cell-in-gel’ and other techniques
for mechanochemotransduction (Prosser et al. 2011; Jian
et al. 2014),mitochondrial imaging (Zhou et al. 2014), and
stem cell technologies (Matsa et al. 2014), just to name a
few.
In addition to the advancement in experimental
techniques, there have been significant gains in
accessibility of modern computing power, computational
speed and reduction in computing cost. Recent advances
have also been made in numerical techniques and
computing (Abramson et al. 2010; Rocha et al. 2011;
Neic et al. 2012; Nivala et al. 2012), the implementation
of customizable solvers such as Continuity, modelling
platforms like CHASTE and OpenCMISS (Bernabeu
et al. 2009; Bradley et al. 2011), and infrastructures
aimed at facilitating standardization, interoperability and
dissemination of models (e.g. CellML and FieldML;
Bernabeu et al. 2009; Christie et al. 2009; Wimalaratne
et al. 2009; Bradley et al. 2011; Quinn et al. 2011).
Mathematical models of cardiac physiology are widely
used to complement experimental findings and clinical
observations to improve understanding of cardiac
electrical function in health and disease. Implementation
of such models offers multiple advantages: In particular
they enable exploration of high-dimensional models to
determine how their range of dynamical behaviours
corresponds to that of low-dimensionalmodels. Emergent
behaviours can be mapped back to underlying
parameters through component dissection, to reveal
mechanisms of emergent behaviours, a function for
which there is no efficient comparable experimental
counterpart.
Experimental approaches and computational
modelling and simulation are complementary methods
to determine how abnormalities in Na+ processes at the
level of the cell can cause emergent arrhythmias in the
whole heart. An example is a hallmark arrhythmia trigger
in human heart failure resulting from Ca2+-induced
DADs. When Na+ accumulation and Ca2+ overload
occurs in cells, DADs arise because the cytosolic Ca2+
accumulation may ultimately exceed Ca2+ efflux via NCX
and precipitate Ca2+ overload. A pathological version
of the Ca2+-induced-Ca2+ release ensues, whereby there
is spontaneous SR Ca2+ release leading to overloaded
intracellular Ca2+ that is extruded by inward NCX
current, which may depolarize the cell sufficiently to
activate Na+ channels leading to the emergence of DADs
and, if large enough, arrhythmogenically triggered action
potentials. Because Na+-mediated Ca2+ overload does
not occur uniformly in time or space, beat-to-beat
variability in repolarization and emergent triggering
of early after-depolarizations (EADs) and DADs occur
unpredictably.
DADs occurring in a single myocyte are an insufficient
source of current to trigger a premature beat in the
whole heart because the current generated in a single
cell is not enough to overcome the large electrotonically
coupled downstream sink. Mathematical models and
experiments in intact hearts have shown that DADs
must occur simultaneously in many thousands of cells
in order to generate an arrhythmia trigger (Hoeker et al.
2009; Xie et al. 2010; Myles et al. 2012). The precise
mechanisms involved in the synchronization of DADs in
many neighbouring cells remain to be resolved. However,
there may be both local electrotonic (Sato et al. 2014) and
Ca2+ handling effects, such as synchronous recovery of
release channel function after the previous normal beat
(Myles et al. 2012).
In the case of loss of Na+ channel function as described
in the infarct border zone, a reduction in excitability at
the cellular level emerges in coupled tissue as slowing
of conduction velocity of the propagating depolarizing
wave that drives cardiac excitation. Slow conduction
can result in an increase in the ‘vulnerable window’ to
result in unidirectional block and, if the conditions are
favourable, retrograde conduction, promoting re-entrant
arrhythmia in the organ (Mines, 1914; Allessie et al.
1973; Starmer et al. 1991, 1993; Starmer, 2002; Moreno
et al. 2011). It is important to note that slow conduction,
when promoted via use-dependent inhibition of INa by
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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drugs for example, can dynamically prolong APD at
the cellular level and QT interval at the organ level as
a result of the intrinsic dynamical properties of Na+
channels and drug–channel interactions that give rise to
the restitution relationship. The restitution relationship
describes the correlation between APD and the pre-
ceding diastolic interval (DI). As the DI increases as a
result of slow conduction, the subsequent AP will be
relatively prolonged. If theDI is sufficiently long and other
anomalies are present, reductions in repolarization reserve
occur and even triggered arrhythmias such as early EADs
may emerge (January&Riddle, 1989; Boutjdir & el-Sherif,
1991; Sicouri et al. 1997; Undrovinas & Maltsev, 2008;
Zaza et al. 2008). Conversely, when the DI is very short,
such as during rapid pacing or tachycardia and combined
with other perturbations such as drugs or disease, the
relationship between APD and DI may be very steep.
In this situation, arrhythmogenic oscillation of the APD
termed alternans can develop. All of these disruptions to
normal cardiac electrical activity promote development of
re-entrant arrhythmias and wavebreak causing fibrillation
(Weiss et al. 2005).
The other effect of loss of Na+ channel function
is slowed conduction that shortens the wavelength
for re-entry. A slowing of the re-entrant wavefront
acts to effectively increase the tissue size and may
promote discordant alternans and allow induction and
maintenance of arrhythmias (Weiss et al. 2011). Na+
channels that are altered by disease or drugs may exhibit
slowed recovery from inactivation, which changes the
conduction velocity (CV) restitution (the relationship
describing the dependency of CV on the inter-beat inter-
val) which combined with APD restitution and/or Ca2+
cycling instabilities promotes spatially discordant APD
alternans to increase dispersion of refractoriness (Weiss
et al. 2011; Sato & Clancy, 2013).
A gain of function of the Na+ channel during
disease that results in an increased INaL has also
been linked to arrhythmias associated with acquired
diseases such as heart failure and post-myocardial
infarction remodelling, due to their impact on action
potential duration and repolarization abnormalities.
Approximately 40% of chronic heart failure patients die
due to sudden cardiac death, with ventricular tachy-
cardia and fibrillation documented in 80% of patients
(Nikolic et al. 1982; Bayes de Luna et al. 1989;
Undrovinas & Maltsev, 2008). Conditions and diseases
that lead to an increased INaL exhibit electrical instability
(due to after-depolarizations, beat-to-beat variability
in repolarization, ventricular arrhythmias), mechanical
instability (impaired diastolic relaxation and ventricular
wall tension, increased diastolic and decreased systolic
force generation), as well as mitochondrial dysfunction.
This sets up a cascade leading to further ischaemia
and abnormal contraction in a pathological feedback
loop. Failing canine ventricular myocytes with prolonged
APs, Ca2+ transients and substantial diastolic Ca2+
accumulation leading to spontaneous Ca2+ release were
shown to improve with TTX and ranolazine (a selective
INaL inhibitor; Wasserstrom et al. 2009; Undrovinas et al.
2010; Antzelevitch et al. 2011). These results are additional
strong indications of the link between pathological INaL to
the induction of derangedCa2+ homeostasis at the cellular
level. A subsequent study using human ventricular myo-
cytes (Maltsev et al. 1998a) similarly found improvement
with TTX.
Figure 1. Schematic depiction of Na+
transport processes in the cardiac myocyte
The figure is reproduced from Despa & Bers
(2013). PLM, phospholemman; SERCA,
sarco/endoplasmic reticulum Ca2+-ATPase.
[Ca]m, mitochondrial Ca2+; ETC, electron
transport chain; PLB, phospholamban; RyR,
ryanodine receptor.
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New therapeutic approaches for Na+-linked
arrhythmias
In the session on ‘Therapeutics’, Robert Kass, Colleen Clancy,
Luiz Belardinelli, Andra´s Varro´, Lazlso Csernoch, Antonio
Zaza, Bernard Fermini and Crystal Ripplinger presented
and discussed current issues in the field. The section below
summarizes these interactions.
As described above, both gain- and loss-of-function
in the cardiac Na+ channel can result in dangerous
proarrhythmic consequences by altering cardiac
repolarization and conduction. Thus, the prospect of
targeted pharmacological treatment to modify Na+-based
arrhythmias has fuelled historical and recent pursuit of
new drugs. However, the history of antiarrhythmic drug
failures makes careful and reliable assessment of drug
effects on cardiac rhythms a preclinical necessity to ensure
safety and efficacy.
The difficulty in predicting drug effects on the
electrical activity of the heart is clear from both the
failure of large clinical trials to demonstrate drug safety
for multiple antiarrhythmic drug classes (for example,
the CAST (1989) and SWORD (Waldo et al. 1996)
clinical trials), and from the market withdrawal of
otherwise promising drugs for treating cardiac dysrhythm,
psychiatric disorders, gastrointestinal symptoms and
infection following unexpected sudden cardiac death
(Drici & Barhanin, 2000). These events have resulted in
a burdensome regulatory process for preclinical drugs
that have discouraged the development and emergence
of potentially therapeutic agents for clinical use.
The reasons that it has been so difficult to predict
ion channel-targeting drug effects on cardiac electrical
activity are that most antiarrhythmic drugs have complex
interactions with multiple channels, conformational state
specificity, bioactive metabolites and neutral and charged
drug fractions. Drugs alter the action potential waveform,
which in turn affects drug potency. Thus, it is extremely
difficult to know how intended antiarrhythmic drugs that
primarily target ion channels will alter emergent electrical
activity in the whole heart.
In the context of pharmacology that is now being
developed to target pathologically enhanced INaL, it must
be emphasized that selective INaL inhibition needs to be
carefully determined (Szel et al. 2011; Belardinelli et al.
2013). In order to assess the specificity of INaL inhibition,
the effect of a candidate drug needs to be thoroughly
screened for its effects on both peak and late INa. Because
peak INa may be differentially affected by drugs at various
heart rates or diastolic voltages, the screening tests must
include an array of assessments to ensure that selectivity
of INaL versus peak INa persists under a variety of physio-
logical conditions. For example, drugs that have relatively
rapid unbinding kinetics may not exhibit obvious effects
on peak INa unless the stimulation rate is sufficiently high.
Moreover, new drugs aimed at selective inhibition of INaL
must be effective in cardiac disease states where hyper-
kalaemia, hypoxia, acidosis and ischaemia are likely.
Question or controversy: predicting therapy
How can critical determinants of drug effects in the
whole heart be predicted from drug targets, kinetics
and active metabolites?
Selective INaL inhibition needs to be clearly defined and
careful determination of drug effects on peak INa needs
to be considered at multiple stimulation frequencies.
Recently, the US Food and Drug Administration (FDA)
and other stakeholders have suggested the potential
implementation of a new pro-arrhythmia safety protocol
that includes testing for the effects of drugs on multiple
cardiac ion channels and integration of this information
using computational modelling and simulation
approaches, and stem cell technologies (Chi, 2013).
Modelling and simulations for predictive pharmacology.
Cardiac modelling and simulation has recently been
utilized to investigate mechanisms of Na+ channel
blocking drugs that both reduce peak Na+ current
and that specifically target INaL. A recent study
investigated lidocaine (lignocaine) effects in a multiscale
computational model (Cardona et al. 2010). The authors
demonstrated both anti-fibrillatory effects in normal
tissue and predicted the potential for pro-arrhythmia
with lidocaine during pathologies including acidosis and
ischaemia, as has also been demonstrated experimentally
due to differential effects of drugs on channels from the
normal and infarct border zones (Pu et al. 1998).
Moreno et al. (2011) also implemented modelling and
simulation approaches to investigate the mechanisms
of failure of the once promising antiarrhythmic drug
flecainide, the subject of the cardiac arrhythmia
suppression trial (CAST), which, in the clinical trial
showed increased mortality with flecainide over placebo
(CAST, 1989). In the computational modelling and
simulation study, the dynamical complexity of the drug
kinetics was modelled for both charged and neutral drug
fractions. After developing the drug–channel model, a
simulation in cells first confirmed experimental findings:
no overt pro-arrhythmic potential was ever observed at
the cellular level (Moreno et al. 2011). In tissue level
simulations, the outcome was very different. Substantial
use-dependent block by flecainide (an intrinsic dynamical
property of channel block) was predicted in the model to
result in failed impulse conduction, a higher dimensional
phenomenon that emerged as a result of increased electro-
tonic load in coupled tissue. Pro-arrhythmic conduction
block led to development of tachycardia indicated by
spiral wave re-entry, which was verified experimentally
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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(Moreno et al. 2011). This emergent phenomenon was
linked back to the fundamental mechanism: the drug
kinetics of unblock, identified as the basic mechanism of
failure. Moreover, the study indicated that the kinetics of
drug interactions for lidocaine promoted safety in higher
dimensions as indicated by no re-entrant arrhythmias in
the presence of lidocaine in normal tissue.
Question or controversy: modelling and simulation
for predictive therapy
It is still not possible to predictively link structural
perturbations to pharmacological effects in the whole
heart.
How to make the model, ‘as simple as possible, but not
simpler’?
Disease-induced enhancement of INaL promotes the
development of arrhythmogenic after-depolarizations,
triggered arrhythmic activity, and torsades de pointes in
cardiac ventricular myocytes, cardiac tissue and intact
hearts (Boutjdir & el-Sherif, 1991; Sicouri et al. 1997;
Clancy & Rudy, 1999; Song et al. 2004; Wu et al. 2006).
Pharmacological targeting of INaL has been shown to
improve cardiac electrical function inmyocytes challenged
by cardiac glycosides, hydrogenperoxide, pharmacological
enhancement of INaL, and even with drugs that block
hERG channels (IKr; the rapidly activating component
of the delayed rectifier potassium current) and reduce
repolarization reserve (Ver Donck et al. 1993; Haigney
et al. 1994; Le Grand et al. 1995; Sicouri et al. 1997; Song
et al. 2004, 2006; Wu et al. 2006; Undrovinas & Maltsev,
2008; Sossalla et al. 2010; Wu et al. 2011).
Recently, modelling and simulation have been used to
probe and predict effects of the selective INaL inhibitor
ranolazine in pathological situations (Moreno et al. 2013).
Simulations of clinically relevant concentrations of drug
wereused topredict the cellular level effects ofNa+ channel
blockade using both ranolazine and its active metabolites
on hERG, which have potent blocking effects in the
therapeutically relevant range. The model was used to
predict if therapeutic effects of targeted pharmacological
treatment by ranolazine prevailed over the unintended
pathological block of hERG for normalizing arrhythmia
triggers (EADs) in bradycardia-dependent arrhythmias in
LQT3, as well as tachyarrhythmogenic triggers arising
from heart failure-induced remodelling (e.g. DADs).
Model predictions suggested that acute targeting of INaL
with ranolazine is an effective therapeutic strategy in
diverse arrhythmia-provoking situations that arise from
a common pathway of increased pathological INaL.
Trenor et al. developed a tool for in silico preclinical
anti-arrhythmic drug safety assessment that predicted
the impact of the IKr/INaL ratio of steady-state block
of drug candidates on ‘torsadogenic’ biomarkers that
they defined as AP duration, triangulation, reverse rate
dependence, transmural dispersion of repolarization and
electrocardiogram QT interval (Trenor et al. 2013).
Although the studies described above included detailed
descriptions of the kinetics of drug interactions with ion
channels, it is important to note that even detailed kinetic
models are phenomenological, for example a Markov
model of ion channel dynamics or drug channel inter-
actions is a phenomenological representation that greatly
simplifies the underlying molecular mechanics. In the
studies described above, it is difficult, if not impossible,
to predictively link atomic scale anomalies to higher order
phenomena, or to predict how structural perturbations
might affect pharmacological effects in thewholeheart.An
important aspect of modelling and simulation as it relates
to the prediction of disease processes and pharmacology is
choosing the level of detail in the model. There must be a
match between the required complexity of the model and
its predictive capacity, so as not to introduce unnecessary
degrees of freedom that result in vastly over-determined
models. In other words, the modeller must be concerned
with the issueof determininghow to, as Einstein suggested,
make the model ‘as simple as possible, but not simpler.’
Stem cells for predictive pharmacology. The potential for
personalizedmedicine via drug screening in patients’ own
induced pluripotent stem cell (hiPSC)-derived cardio-
myocytes (hiPSC-CMs) (Braam et al. 2010) is another
developing and exciting application at the interface
of molecular and clinical information (Liang et al.
2013; Sallam et al. 2014). Patient-specific hiPSC-CMs
containing unknown genotype profiles, or with known
polymorphisms and/or mutations in cardiac ion channels
can be used to qualitatively and quantitatively assess
variability in drug responses (Matsa et al. 2014).
Thus far, iPSC-CMs have been used to successfully
model arrhythmic disorders, with excellent agreement
between altered cardiac channel function and emergent
electrophysiological phenotypes in the inherited long
QT syndromes and catecholaminergic polymorphic
ventricular tachycardia (Sallam et al. 2014). Indeed, the
ion channel, Ca2+ handling and signalling in hiPSC-CMs
still differ substantially from those in adult cardiac
myocytes.
Question or controversy: patient-derived induced
pluripotent stem cell (hiPSC)-derived cardio-
myocytes
Ca2+ handling and signalling in hiPSC-CMs still differ
substantially from those in adult cardiac myocytes.
Many challenges need to be overcome before stem cell
technologies enter the mainstream for drug screening
and therapy.
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Terrenoire et al. recently demonstrated the usefulness
of such an approach in a study where they derived iPSCs
from a long QT syndrome patient with complex genetics
(Terrenoire et al. 2013). They identified a de novomutation
in the SCN5A (F1473C) gene encoding the NaV1.5, and
a polymorphism (K897T) in KCNH2, the gene encoding
hERG. Biophysical and pharmacological analysis of ion
channels expressed in iPSC-CMs demonstrated that the
disease was a primary consequence of the NaV1.5 defect
and was not influenced by the KCNH2 polymorphism.
Themutation resulted in a gain-of-function in INaL, which
resulted in delayed repolarization, a prolonged QT inter-
val, and increased risk of arrhythmia. They also found a
uniquely steep fast-rate-dependent reduction in INaL that
especially facilitated pharmacological inhibition by the
Na+ channel inhibitor mexiletine. Of critical importance,
the experiments revealed rate-dependent properties of
ion currents and drug interactions that were unique to
the patient’s iPSC-CMs, and that were corroborated in
a successful patient treatment regimen. This study is
an example of the potential of iPSC-CM approaches in
developing patient-specific clinical regimens (Terrenoire
et al. 2013).
While the study described above focused on a gain of
function perturbation in the Na+ channel, and its cellular
level effects, iPSC-CMs can also be cultured in mono-
layer or grown on scaffolds to investigate patient-specific
metrics related to loss of Na+ channel function, especially
conduction velocity. For example, measurements of
voltage wavefronts inmonolayers of iPSC-CMs via optical
mapping has recently been demonstrated (Chen et al.
2011).
The potential for expansion of stem cell technologies
in the cardiac therapeutic arena is vast (Liang et al.
2013; Mordwinkin et al. 2013). For example, these cells
may prove extremely useful to reveal some of the most
basic variations in drug responses that might include the
influenceof sex, polytherapy, hormones anddrug effects in
the context of genetically based diseases. Examples include
the apparent differential effects of hERGblockade inmales
and females, oral contraceptive effects on cardiac risk, or to
determine the electrophysiological effects of β-blockers in
LQT3 patients (Kurokawa et al. 2008; Ahrens-Nicklas et al.
2009; Abu-Zeitone et al. 2014). However, many challenges
still need to be overcome inorder for stemcell technologies
to enter themainstream for screening and therapy. Toward
this goal, best practices are in development to improve
the maturity and homogeneity of electrical activity in
iPSC-derivedmyocytes (Bett et al. 2013;Hulot et al. 2014).
Summary
In order to begin to translate the new findings on Na+
derangement in the heart and its link to disease processes
to effective patient interventions, there must be a specific
and concerted collaboration between the many scientific
investigators at the bench, the computer terminal and
the bedside. Such an effort would allow more immediate
application of critical research findings and predictions
to more rapidly improve outcomes for patients with
cardiac disease states that are marked by disruptions in
ion homeostasis. Consideration of patient-specific disease
and therapeutics should be part of the consortium effort.
A critical requirement for developing interdisciplinary
efforts to promote understanding and knowledge among
stakeholders in the field is to ‘get them together in a
room’ for discussion anddebate regarding themost critical
aspects that need to be addressed. Indeed, the UC Davis
Cardiovascular Symposium in 2014 on Na+ in the heart
aimed to do exactly this: bring together the world’s topical
experts to engage in scientific dialogue and debate tomove
the field forward.
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